Silence: 'Buy' Zerlasiran Program Shift And Divesiran Results August 2026

2026-06-12 16:26:07 ET

The last time I spoke about Silence Therapeutics ( SLN ) it was with a Seeking Alpha article entitled " Silence: Additional siRNA Drug Data Leads To Next Stages Of Development ." With respect to this article, I mentioned that the company was in the process of developing its first-in-class small interfering RNA [siRNA] therapy targeting TMPRSS6 drug candidate divesiran for the treatment of patients with polycythemia vera [PV] in the ongoing phase 1 SANRECO study. In addition, I also mentioned that the company was gearing up to potentially initiate a phase 3 study using its other siRNA candidate zelrasiran for the treatment of patients with elevated levels of Lp[a] at high risk of atherosclerotic cardiovascular disease [ASCVD]....

Read the full article on Seeking Alpha

For further details see: